Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488978 | 0.90 | PPARD (0.50) | PPARDPOLBHDAC1ENPP2NR1I2 | |
| SCHEMBL1489170 | 0.83 | NPY5R (0.45) | ALDH1A1POLBAPEX1TDP1KDM4E | |
| SCHEMBL915441 | 0.83 | PPARD (0.44) | ALDH1A1PPARDPOLBKDM4EHDAC1 | |
| SCHEMBL914541 | 0.83 | PPARD (0.44) | ALDH1A1PPARDPOLBKDM4EHDAC1 | |
| SCHEMBL12648165 | 0.81 | PPARD (0.42) | PPARDPOLBHDAC1ENPP2 | |
| SCHEMBL914602 | 0.81 | PPARD (0.42) | ALDH1A1PPARDPOLBTDP1KDM4E | |
| SCHEMBL5051393 | 0.81 | KMT2A (0.44) | PPARDPOLBHDAC1ENPP2KMT2A | |
| SCHEMBL915280 | 0.81 | FDPS (0.46) | ALDH1A1PPARDPOLBTDP1HDAC1 | |
| SCHEMBL915800 | 0.81 | TSHR (0.52) | PPARDPOLBKMT2ANR1I2GAA | |
| SCHEMBL1401011 | 0.80 | TDP1 (0.45) | ALDH1A1POLBAPEX1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500417-A | ANTIARTHRITIC | THE UPJOHN COMPANY (US) | 1996-03-19 | — | — | US | claimed |
| EP-0661978-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1994007501-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1994-04-14 | — | — | WO | claimed |
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1981888-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | Pharmacyclics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007087068-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006086609-A2 | INHIBITORS OF TRYPTASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | ALDH1A1 2984/4885PPARD 4109/4885POLB 1986/4885 |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | ALDH1A1 2984/4885PPARD 4109/4885POLB 1986/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | ALDH1A1 2984/4885PPARD 4109/4885POLB 1986/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | ALDH1A1 2984/4885PPARD 4109/4885POLB 1986/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | ALDH1A1 2984/4885PPARD 4109/4885POLB 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.